3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
28
Neoplasm Metastasis
6
Recurrence
5
Breast Neoplasms
4
Stomach Neoplasms
3
Prostate Cancer Metastatic
3
Neoplastic Cells, Circulating
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Penile Neoplasms
1
Nonseminomatous germ cell tumor
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lung Neoplasms
1
Liposarcoma
1
Hormone-Resistant Prostate Cancer
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Diarrhea
1
Interventions
cabazitaxel
3
Trastuzumab
3
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
ribociclib
1
pertuzumab
1
eribulin
1
Thiotepa
1
Taxes
1
Stem Cell Transplantation
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liquid Biopsy
1
Letrozole
1
Ipilimumab
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Gemcitabine
1
Fulvestrant
1
Epirubicin
1
Docetaxel
1
Denosumab
1
Circulating Tumor DNA
1
Cell-Free Nucleic Acids
1
CA-72-4 antigen
1
CA-19-9 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplastic Cells, Circulating
×
cabazitaxel
×
Clear all
NCT03101046
2022-02-10
TACTIK
UNICANCER
Phase 2
Completed
40 enrolled
NCT03050866
2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2
Unknown
140 enrolled
NCT02621190
2016-08-17
CARVE
Erasmus Medical Center
Phase 2
Withdrawn